Jaweher Bday | Cancer Research | Best Researcher Award

Published on by Oncology

Ms. Jaweher Bday | Cancer Research | Best Researcher Award 

PhD Student | Higher Institute of Biotechnology of Monastir | Tunisia

Ms. Jaweher Bday is a highly promising PhD researcher in biotechnology with a robust specialization in immuno-oncology, demonstrating strong potential and clear suitability for a Best Researcher Award through her scientific rigor, technical depth, and impactful research outputs. Her academic journey—from a bachelor’s degree in molecular and cellular biology, a research master’s in cell biology and physiology, to an ongoing PhD at the Higher Institute of Biotechnology of Monastir—illustrates continuous progression and dedication to cancer research. She has completed several competitive international research internships in leading laboratories in France, including the Bio PeroxIL Laboratory at the University of Burgundy and the INSERM U1307 Laboratory at the University of Nantes, enhancing her expertise in cell death mechanisms, tumor biology, and advanced molecular techniques. Her publication record is strong and growing, with peer-reviewed articles in recognized journals on topics such as arginase regulation in HPV infection, hybrid cell-death induction in breast cancer models, and the role of nitric oxide pathways in cervical carcinogenesis, along with an additional submitted manuscript on HPV circulating markers. Jaweher’s scientific maturity is evidenced by her active participation in conferences, including oral and poster presentations at national and international oncology and toxicology meetings, reflecting substantial dissemination of her research. Beyond laboratory excellence, she demonstrates leadership through major roles in the Tunisian Association of Biotechnology Students, including serving as President and spearheading scientific events and innovation-focused programs. Her teaching activities, spanning workshops, directed courses, and hands-on training, further showcase her commitment to academic development and knowledge transfer. Equipped with advanced laboratory skills, strong analytical proficiency using tools like FlowJo, ImageJ, SPSS, and GraphPad, along with extensive training in scientific writing, publishing, quality management, and pedagogy, she embodies the qualities of an emerging researcher with both scientific impact and community engagement. Overall, her achievements, productivity, international exposure, and leadership make her an excellent candidate for a Best Researcher Award.

Profile: ORCID

Featured Publications

  1. Souid, M., Bday, J., Souissi, S., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Toumi, D., Bergaoui, H., Zouari, I., Faleh, R., Zakhama, A., & Hassen, E. (2023). Arginase is upregulated in healthy women infected by oncogenic HPV types. Biomarkers, 28(7), 628–636.

  2. Bday, J., Souid, M., Pires, V., Gabbouj, S., Véjux, A., Lizard, G., & Hassen, E. (2025). Arginase activity inhibition with thymoquinone induces a hybrid type of cell death in MDA-MB-231 cell line. Journal of Biochemical and Molecular Toxicology, 39(2), e70130.

  3. Bday, J., Souid, M., Farhat, K. H., Macherki, Y., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Faleh, R., & Hassen, E. (2025). Involvement of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) levels in precancerous and cancerous cervical lesions. Nitric Oxide, 159, 176–185.

  4. Souid, M., Ghedira, R., Bday, J., Gabbouj, S., Shini-Hadhri, S., Hajji, A., Faleh, R., & Hassen, E. (Under review). Human Papillomavirus-16 circulating markers distribution among unvaccinated women. Infectious Diseases Now.

  5. Bday, J., Souid, M., Pires, V., Véjux, A., Lizard, G., & Hassen, E. (2025). Hybrid cell-death mechanisms in breast cancer: Insights from thymoquinone-mediated arginase inhibition. Manuscript in preparation.

Ms. Jaweher Bday’s work advances immuno-oncology by uncovering novel cellular and molecular mechanisms that can drive more precise cancer diagnostics and targeted therapies. Her research contributes to global health by improving understanding of HPV-related cancers and breast cancer biology, supporting innovations that can shape future clinical and translational applications. Through scientific leadership, teaching, and community engagement, she helps strengthen research capacity and fosters the next generation of biotechnology innovators.

Assoc Prof Dr.Marwa Muhammad Abu-Serie Ali – Targeted Cancer Therapy – Best Researcher Award

Published on by Oncology

Assoc Prof Dr.Marwa Muhammad Abu-Serie Ali - Targeted Cancer Therapy - Best Researcher Award

SRTA city - Egypt

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS:

Marwa Muhammad Abu-Serie Ali initiated her academic journey in the field of biochemistry, obtaining a Bachelor's degree from Alexandria University, Egypt, with honors. She continued her academic pursuits with a Master's degree in Biochemistry from the same university in 2008. Later, in 2014, Marwa achieved a significant milestone by completing her Ph.D. in the Biochemistry Department at the Faculty of Science, Alexandria University, Egypt. Her doctoral thesis focused on a model for drug assessment of colon cancer induced in murine cells.

PROFESSIONAL ENDEAVORS:

Marwa's professional journey encompasses various roles, starting from a Delegated Demonstrator at Alexandria University to her current position as an Associate Professor in the Medical Biotechnology Department at the Genetic Engineering and Biotechnology Research Institute (GEBRI) in Egypt. She has consistently contributed to research and academia, progressing from Assistant Researcher to Researcher and eventually to her current leadership position as an Associate Professor.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

Marwa's research focus is on medical biotechnology, with specific interests in tageted cancer therapy studies. Her work includes projects such as the assessment of nanotherapeutic approaches in colon cancer, the development of anti-coronavirus agents, and the evaluation of novel anticancer agents. She has also explored the anti-tumor efficacy of various formulations against different types of carcinoma, emphasizing a comprehensive and innovative approach to cancer treatment.

IMPACT AND INFLUENCE:

Marwa has made significant contributions to the scientific community through her involvement in research projects funded by prestigious organizations like the Science & Technology Development Fund (STDF), Fulbright, and the Academy of Scientific Research and Technology Center (STC). Her work has not only expanded scientific knowledge but has also paved the way for potential breakthroughs in cancer treatment and the fight against infectious diseases.

ACADEMIC CITATIONS:

Marwa's academic work has likely garnered citations in various research publications, reflecting the impact of her contributions to the field of medical biotechnology. These citations signify the acknowledgment and recognition of her research by peers and fellow scientists.

LEGACY AND FUTURE CONTRIBUTIONS:

Marwa's legacy lies in her commitment to advancing knowledge in medical biotechnology, particularly in cancer research and antiviral drug development. Her future contributions are anticipated to further shape the landscape of biomedical research, potentially leading to breakthroughs in cancer treatment and viral therapeutics.

NOTABLE PUBLICATIONS

Anticancer activity of lactoferrin-coated biosynthesized selenium nanoparticles for combating different human cancer cells via mediating apoptotic effects.2023

Inhibitory effect of lactoferrin-coated zinc nanoparticles on SARS-CoV-2 replication and entry along with improvement of lung fibrosis induced in adult male albino rats.2023

Concurrent Tissue Engineering for Wound Healing in Diabetic Rats Utilizing Dual Actions of Green Synthesized CuO NPs Prepared from Two Plants Grown in Egypt.2023